日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study

Simlukafusp alfa (FAP-IL2v) 联合阿特珠单抗,加或不加贝伐珠单抗,用于治疗不可切除的转移性肾细胞癌:一项随机、开放标签的 Ib 期研究

Perez-Gracia, Jose Luis; Mellado, Begoña; Hansen, Aaron Richard; Alonso-Gordoa, Teresa; Gomez-Roca, Carlos; Løvendahl Eefsen, Rikke; Negrier, Sylvie; Suárez, Cristina; Lee, Jae-Lyun; Hussain, Arif; Pedrazzoli, Paolo; Moreno, Victor; Rodriguez-Vida, Alejo; Sosman, Jeffrey Alan; Waddell, Tom; Bedke, Jens; Park, Se Hoon; Sznol, Mario; Spychaj, Lukasz; Andersson, Emilia; Julien-Laferriere, Alice; Cheng, Wei-Yi; Watson, Carl; Silva, Ana Patricia; Heichinger, Christian; Staedler, Nicolas; Sleiman, Nassim; Dejardin, David; Boetsch, Christophe; Evers, Stefan; Vardar, Taner; Ardeshir-Tandon, Caroline; Dorado Pérez, Jorge; Charo, Jehad; Keshelava, Nino; Kraxner, Anton; Teichgräber, Volker; Powles, Thomas

Role of Local Treatment to the Prostate in Patients With de Novo Low-volume Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors

局部治疗在接受雄激素受体通路抑制剂治疗的初发低肿瘤负荷转移性激素敏感性前列腺癌患者中的作用

Mandel, Philipp; Wenzel, Mike; Chun, Felix; Graefen, Markus; Gandur Quiroga, María Natalia; Rodriguez-Vida, Alejo; Bourlon, Maria T; Myint, Zin W; Bernal, Laura; Ürün, Yüksel; Kopp, Ray Manneh; Juan Fita, Maria José; Zapata Laguado, Martin Ignacio; Büttner, Thomas; Fiala, Ondrej; Fujita, Kazutoshi; Li, Haoran; Kopecky, Jindrich; Matrana, Marc R; Bögemann, Martin; Carrozza, Francesco; Zgura, Anca; Buchler, Tomas; Matthews, Diana; Yazgan, Sati Coskun; Lenci, Edoardo; Ansari, Jawaher; Marques Monteiro, Fernando Sabino; Soares, Andrey; Rizzo, Alessandro; Ciccimarra, Francesco; Massari, Francesco; Jazieh, Abdul Rahman; Santoni, Matteo

Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors

通过上调PD-L1增强免疫疗法:抗PD-L1抑制剂联合mTOR抑制剂的前景广阔

Anna Hernández-Prat ,Alejo Rodriguez-Vida ,Laura Cardona ,Mengjuan Qin ,Oriol Arpí-Llucià ,Luis Soria-Jiménez ,Sílvia Menendez ,Fabricio Gerel Quimis ,Miguel Galindo ,Edurne Arriola ,Marta Salido ,Nuria Juanpere-Rodero ,Federico Rojo ,Aura Muntasell ,Joan Albanell ,Ana Rovira ,Joaquim Bellmunt

Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression

转移性激素敏感性前列腺癌患者PTEN表达低表达的临床和转录组学特征分析

Garcia de Herreros, Marta; Jiménez, Natalia; Padrosa, Joan; Aversa, Caterina; Ferrer-Mileo, Laura; García-Esteve, Samuel; Rodríguez-Carunchio, Leonardo; Trias, Isabel; Fernández-Mañas, Laia; Marín-Aguilera, Mercedes; Altamirano, Mariana; Mazariegos, Manuel; Font, Albert; Rodriguez-Vida, Alejo; Climent, Miguel Ángel; Cros, Sara; Chirivella, Isabel; Figols, Mariona; Sala-González, Núria; Ruiz de Porras, Vicenç; Pardo, Juan Carlos; Prat, Aleix; Reig, Òscar; Mellado, Begoña

Tumor B cell infiltration in platinum-treated advanced urothelial carcinoma

铂类药物治疗的晚期尿路上皮癌中肿瘤B细胞浸润

Stawiski, Konrad; Perera-Bel, Júlia; Rodriguez-Vida, Alejo; Juanpere Rodero, Núria; Lee, Jihyun; Michaud, Daniel E; Guerriero, Jennifer L; Mouw, Kent W; Bamias, Aristotelis; Carvalho, Filipe Lf; Bellmunt, Joaquim

Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma

肿瘤突变负荷和PD-L1与帕博利珠单抗联合或不联合化疗治疗晚期尿路上皮癌疗效的相关性

Fléchon, Aude; Morales-Barrera, Rafael; Powles, Thomas; Alva, Ajjai; Özgüroğlu, Mustafa; Csöszi, Tibor; Loriot, Yohann; Rodriguez-Vida, Alejo; Géczi, Lajos; Cheng, Susanna Y; Fradet, Yves; Oudard, Stéphane; Vulsteke, Christof; Gunduz, Seyda; Mamtani, Ronac; Yu, Evan Y; Montesa Pino, Alvaro; Anido, Urbano; Sendur, Mehmet A N; Gravis, Gwenaelle; Révész, János; Kostorov, Vladimir; Huillard, Olivier; Ma, Junshui; Rajasagi, Mohini; Vajdi, Amir; Lunceford, Jared; Cristescu, Razvan; Imai, Kentaro; Homet Moreno, Blanca; Matsubara, Nobuaki

Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

在不适合接受顺式治疗的转移性尿路上皮癌患者中,一线治疗方案为阿维鲁单抗诱导治疗后序贯化疗免疫疗法和维持治疗与单纯化疗的疗效比较(INDUCOMAIN):一项随机II期研究

Rodriguez-Vida, A; Valderrama, B P; Castellano, D; Pinto, A; Mellado, B; Puente, J; Climent, M A; Domenech, M; Vazquez, F; Perez-Gracia, J L; Bonfill, T; Morales-Barrera, R; Gonzalez-Billalabeitia, E; Garcia-Del-Muro, X; Maroto, P; Navarro-Gorro, N; Juanpere, N; Juan, O; Bellmunt, J

Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)

阿法替尼治疗ERBB1-3基因改变的晚期尿路上皮癌患者的II期试验(LUX-Bladder 1)

Font, Albert; Mellado, Begona; Climent, Miguel A; Virizuela, Juan Antonio; Oudard, Stephane; Puente, Javier; Castellano, Daniel; González-Del-Alba, Aranzazu; Pinto, Alvaro; Morales-Barrera, Rafael; Rodriguez-Vida, Alejo; Fernandez, Pedro L; Teixido, Cristina; Jares, Pedro; Aldecoa, Iban; Gibson, Neil; Solca, Flavio; Mondal, Shoubhik; Lorence, Robert M; Serra, Josep; Real, Francisco X

Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors

转化生长因子-β (TGFβ) 抑制剂 SAR439459 作为单一疗法和与 cemiplimab 联合治疗晚期实体肿瘤患者的 I 期临床研究的生物标志物和药效学活性

Debbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, Matteo Simonelli, Bernard Doger, Ivan Borbath, Marcus O Butler, Tina Cheng, Patricia Martin Romano, Elvire Pons-Tostivint, Massimo Di Nicola, Giuseppe Curigliano, Min-Hee Ryu, Alejo Rodriguez-Vida, Dirk Schadendorf, Elena Garralda, Giovanni Abbade

Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer

免疫组织化学标志物作为多灶性前列腺癌预后的预测指标

Segalés, Laura; Juanpere, Nuria; Gallarín, Nerea; Lorenzo, Marta; López, David; Perera-Bel, Júlia; Rodriguez-Vida, Alejo; Fumadó, Lluís; Cecchini, Lluís; Bellmunt, Joaquim; Lloreta-Trull, Josep; Hernández-Llodrà, Silvia